论文部分内容阅读
目的研究异甘草酸镁对难治性肾病综合征患者药物所致肝损伤的临床疗效。方法选择2014年3月—2015年12月在内蒙古林业总医院进行诊治的因治疗药物引起肝损伤的难治性肾病综合征患者86例,按数字法随机分为两组,对照组给予复方甘草酸单胺,观察组给予异甘草酸镁,均治疗2周。分别于治疗前后检测天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、谷氨酰转肽酶(y-GT)、总胆汁酸(TBA)等肝功能指标;并记录患者临床症状和体征的复常情况,临床疗效以及不良反应发生情况。结果治疗前两组AST、ALT、y-GT、TBA比较,差异无显著性;两组治疗后的AST、ALT、y-GT、TBA均明显降低(P<0.05),且观察组的降低程度明显优于对照组(P<0.05);观察组的临床症状和体征改善情况明显优于对照组(P<0.05),且观察组的临床症状和体征复常时间明显短于对照组(P<0.05);观察组有效率为95.35%,明显高于对照组79.07%(P<0.05);两组不良反应发生率相比无明显差异。结论异甘草酸镁能明显改善难治性肾病综合征患者药物所致肝损伤,安全有效,具有较高的临床应用价值。
Objective To study the clinical effect of magnesium isrimazole on drug-induced liver injury in patients with refractory nephrotic syndrome. Methods Eighty-six patients with refractory nephrotic syndrome who were diagnosed as liver injury caused by treatment of drugs in the Inner Mongolia Forestry General Hospital from March 2014 to December 2015 were randomly divided into two groups according to the digital method. The control group was given compound licorice Acid monoamine, observation group given magnesium isoglycyrrhizinate, were treated for 2 weeks. The liver function indexes such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), glutamyl transpeptidase (y-GT) and total bile acid (TBA) were measured before and after treatment. Record the patient’s clinical symptoms and signs of the normal situation, clinical efficacy and adverse reactions. Results There was no significant difference in AST, ALT, y-GT and TBA between the two groups before treatment. The levels of AST, ALT, y-GT and TBA in both groups were significantly decreased (P <0.05) (P <0.05). The improvement of clinical symptoms and signs in the observation group was significantly better than that in the control group (P <0.05), and the clinical symptoms and signs of the observation group were significantly shorter than those in the control group (P < 0.05). The effective rate of the observation group was 95.35%, which was significantly higher than that of the control group (79.07%, P <0.05). There was no significant difference between the two groups in the incidence of adverse reactions. Conclusion Isoglycyrrhizinate can obviously improve the drug-induced liver injury in patients with refractory nephrotic syndrome, which is safe and effective, and has high clinical value.